Literature DB >> 12566288

Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics.

Marios Hadjivassiliou1, Richard Grünewald, Basil Sharrack, David Sanders, Alan Lobo, Clare Williamson, Nicola Woodroofe, Nicholas Wood, Aelwyn Davies-Jones.   

Abstract

We previously have described a group of patients with gluten sensitivity presenting with ataxia (gluten ataxia) and suggested that this disease entity may account for a large number of patients with sporadic idiopathic ataxia. We have therefore investigated the prevalence of gluten sensitivity amongst a large cohort of patients with sporadic and familial ataxia and looked at possible genetic predisposition to gluten sensitivity amongst these groups. Two hundred and twenty-four patients with various causes of ataxia from North Trent (59 familial and/or positive testing for spinocerebellar ataxias 1, 2, 3, 6 and 7, and Friedreich's ataxia, 132 sporadic idiopathic and 33 clinically probable cerebellar variant of multiple system atrophy MSA-C) and 44 patients with sporadic idiopathic ataxia from The Institute of Neurology, London, were screened for the presence of antigliadin antibodies. A total of 1200 volunteers were screened as normal controls. The prevalence of antigliadin antibodies in the familial group was eight out of 59 (14%), 54 out of 132 (41%) in the sporadic idiopathic group, five out of 33 (15%) in the MSA-C group and 149 out of 1200 (12%) in the normal controls. The prevalence in the sporadic idiopathic group from London was 14 out of 44 (32%). The difference in prevalence between the idiopathic sporadic groups and the other groups was highly significant (P < 0.0001 and P < 0.003, respectively). The clinical characteristics of 68 patients with gluten ataxia were as follows: the mean age at onset of the ataxia was 48 years (range 14-81 years) with a mean duration of the ataxia of 9.7 years (range 1-40 years). Ocular signs were observed in 84% and dysarthria in 66%. Upper limb ataxia was evident in 75%, lower limb ataxia in 90% and gait ataxia in 100% of patients. Gastrointestinal symptoms were present in only 13%. MRI revealed atrophy of the cerebellum in 79% and white matter hyperintensities in 19%. Forty-five percent of patients had neurophysiological evidence of a sensorimotor axonal neuropathy. Gluten-sensitive enteropathy was found in 24%. HLA DQ2 was present in 72% of patients. Gluten ataxia is therefore the single most common cause of sporadic idiopathic ataxia. Antigliadin antibody testing is essential at first presentation of patients with sporadic ataxia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566288     DOI: 10.1093/brain/awg050

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  59 in total

1.  The many faces of celiac disease.

Authors:  Vivian Asamoah; Ranier von Coelln; Joseph Savitt; Linda A Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-08

2.  Antigliadin antibody in an ataxic patient with no other evidence of celiac sprue.

Authors:  Brad E Maltz; Terrence A Smith
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-04

3.  Review.

Authors:  Mohammad Azam; Maire Buckley; Richard J Farrell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-04

4.  Serology of celiac disease in gluten-sensitive ataxia or neuropathy: role of deamidated gliadin antibody.

Authors:  Shahrooz Rashtak; Shadi Rashtak; Melissa R Snyder; Sean J Pittock; Tsung-Teh Wu; Manish J Gandhi; Joseph A Murray
Journal:  J Neuroimmunol       Date:  2010-11-06       Impact factor: 3.478

Review 5.  The neurology of enteric disease.

Authors:  A J Wills; D S N A Pengiran Tengah; G K T Holmes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-30       Impact factor: 10.154

6.  Celiac sprue: a unique autoimmune disorder.

Authors:  Shadi Rashtak; Eric V Marietta; Joseph A Murray
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

Review 7.  Celiac disease and autoimmunity in the gut and elsewhere.

Authors:  Susan H Barton; Joseph A Murray
Journal:  Gastroenterol Clin North Am       Date:  2008-06       Impact factor: 3.806

Review 8.  Immunologically mediated dementias.

Authors:  Michael H Rosenbloom; Sallie Smith; Gulden Akdal; Michael D Geschwind
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

9.  Dietary treatment of gluten ataxia.

Authors:  M Hadjivassiliou; G A B Davies-Jones; D S Sanders; R A Grünewald
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

10.  Gluten encephalopathy with psychiatric onset: case report.

Authors:  Nicola Poloni; Simone Vender; Emilio Bolla; Paola Bortolaso; Chiara Costantini; Camilla Callegari
Journal:  Clin Pract Epidemiol Ment Health       Date:  2009-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.